Abstract:Context: Visceral pain is a leading symptom for patients with irritable bowel syndrome (IBS) that affects 10% - 20 % of the world population. Conventional pharmacological treatments to manage IBS-related visceral pain is unsatisfactory. Recently, medications have emerged to treat IBS patients by targeting the gastrointestinal (GI) tract and peripheral nerves to alleviate visceral pain while avoiding adverse effects on the central nervous system (CNS). Several investigational drugs for IBS also target the periphery with minimal CNS effects. Evidence of acquisition: In this paper, reputable internet databases from 1960 - 2016 were searched including Pubmed and ClinicalTrials.org, and 97 original articles analyzed. Search was performed based on the following keywords and combinations: irritable bowel syndrome, clinical trial, pain, visceral pain, narcotics, opioid, chloride channel, neuropathy, primary afferent, intestine, microbiota, gut barrier, inflammation, diarrhea, constipation, serotonin, visceral hypersensitivity, nociceptor, sensitization, hyperalgesia. Results: Certain conventional pain managing drugs do not effectively improve IBS symptoms, including NSAIDs, acetaminophen, aspirin, and various narcotics. Anxiolytic and antidepressant drugs (Benzodiazepines, TCAs, SSRI and SNRI) can attenuate pain in IBS patients with relevant comorbidities. Clonidine, gabapentin and pregabalin can moderately improve IBS symptoms. Lubiprostone relieves constipation predominant IBS (IBS-C) while loperamide improves diarrhea predominant IBS (IBS-D). Alosetron, granisetron and ondansetron can generally treat pain in IBS-D patients, of which alosetron needs to be used with caution due to cardiovascular toxicity. The optimal drugs for managing pain in IBS-D and IBS-C appear to be eluxadoline and linaclotide, respectively, both of which target peripheral GI tract. Conclusions: Conventional pain managing drugs are in general not suitable for treating IBS pain. Medications that target the GI tract and peripheral nerves have better therapeutic profiles by limiting adverse CNS effects.

Chronic abdominal pain in irritable bowel syndrome – current and future therapies

Pharmacological Approach for Managing Pain in Irritable Bowel Syndrome: A Review Article

Chronic abdominal pain in inflammatory bowel disease: a practical guide

Advances in the Research and Treatment of Spinal Endogenous Abdominal Pain

Irritable bowel syndrome: recent and novel therapeutic approaches

Mast cell modulation: A novel therapeutic strategy for abdominal pain in irritable bowel syndrome

Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians

Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches

Irritable bowel syndrome - from etiopathogenesis to therapy

Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance

Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome

[Irritable bowel syndrome: current treatment options]

Current and novel therapeutic options for irritable bowel syndrome management

New drugs in the management of the irritable bowel syndrome

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review

Advances in the pathological mechanisms and clinical treatments of chronic visceral pain

Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview

Psychotherapeutic Interventions in Irritable Bowel Syndrome

Irritable Bowel Syndrome: A Review and Update

Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome

The Brain-Gut Axis in Abdominal Pain Syndromes